Rein Therapeutics Q2 EPS $(0.10) Beats $(0.17) Estimate
Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.17) by 41.18 percent. This is a 64.29 percent increase over losses of $(0.28) per share
Rein Therapeutics lost less money than experts predicted—that's a win when a company is still in the red. Watch whether the company keeps improving and getting closer to actually making money.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.